VOR BIOPHARMA INC (VOR) Stock Price & Overview
NASDAQ:VOR • US9290332074
Current stock price
The current stock price of VOR is 13.81 USD. Today VOR is down by -5.54%. In the past month the price increased by 1.77%. In the past year, price decreased by -4.08%.
VOR Key Statistics
- Market Cap
- 674.619M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -26.49
- Dividend Yield
- N/A
VOR Stock Performance
VOR Stock Chart
VOR Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to VOR. When comparing the yearly performance of all stocks, VOR is a bad performer in the overall market: 80.17% of all stocks are doing better.
VOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VOR. While VOR seems to be doing ok healthwise, there are quite some concerns on its profitability.
VOR Earnings
VOR Forecast & Estimates
13 analysts have analysed VOR and the average price target is 38.38 USD. This implies a price increase of 177.9% is expected in the next year compared to the current price of 13.81.
VOR Groups
Sector & Classification
VOR Financial Highlights
Over the last trailing twelve months VOR reported a non-GAAP Earnings per Share(EPS) of -26.49. The EPS increased by 22.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -149.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VOR Ownership
VOR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 351.47B | ||
| AMGN | AMGEN INC | 15.09 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.44 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.23 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VOR
Company Profile
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 159 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
Company Info
IPO: 2021-02-05
VOR BIOPHARMA INC
500 Boylston Street, Suite 1350
Boston MASSACHUSETTS US
Employees: 76
Phone: 16176556580
VOR BIOPHARMA INC / VOR FAQ
What does VOR do?
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 159 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
What is the current price of VOR stock?
The current stock price of VOR is 13.81 USD. The price decreased by -5.54% in the last trading session.
Does VOR stock pay dividends?
VOR does not pay a dividend.
What is the ChartMill technical and fundamental rating of VOR stock?
VOR has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for VOR stock?
13 analysts have analysed VOR and the average price target is 38.38 USD. This implies a price increase of 177.9% is expected in the next year compared to the current price of 13.81.
Can you provide the ownership details for VOR stock?
You can find the ownership structure of VOR BIOPHARMA INC (VOR) on the Ownership tab.